Development of monoclonal antibodies to prevent and treat infections from Flaviviruses[E8]

Aus der Bekanntmachung

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The capacity to produce antibodies that can target new variants and rapidly increase production would serve as an essential preparedness strategy against future health threats, whether from infectious disease epidemics or pandemics. This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the imp…[E3]

Die Angaben der Bekanntmachung werden so gezeigt, wie die Quelle sie veröffentlicht hat. Die Fakten und Anforderungen, die wir herausziehen, sind auf Englisch.

• Offen fürUniversities and research. Von SLETOR anhand der Wörter der Ausschreibung zugeordnet.
• BedingungEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• RisikoThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• UnbekanntWe read the funder's listing, not the full guidance or application forms.

1. Für Angebote geöffnet · 29. Okt. 2026, 07:41 UTC

   The funder published the call with a future closing date.

   Geändert: status, notice type, published at (Quelldatensatz Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06))

2. Erstmals gesehen · 28. Okt. 2026, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   Quelldatensatz: Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06)

Jede Angabe auf dieser Seite stammt aus der Ausschreibung des Fördergebers. Jeder Eintrag zeigt den Datensatz und das Feld, aus dem er gelesen wurde.

1. E1

   The funder is European Commission.

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/type/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/deadlineDate/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/descriptionByte/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/type/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

5. E5

   This is an EU call for proposals.

   “31094502”

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/status/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/startDate/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/status/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

8. E8

   The notice is titled "Development of monoclonal antibodies to prevent and treat infections from Flaviviruses".

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/title/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   Aus Development of monoclonal antibodies to prevent and treat infections from Flavi… (ID HORIZON-HLTH-2027-01-DISEASE-06), Feld /metadata/budgetOverview/0, gelesen 29. Okt. 2026, 07:41 UTC · Quelle ↗ (öffnet in neuem Tab)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Datenlizenz: Creative Commons Attribution 4.0 (European Commission) ↗ (öffnet in neuem Tab). Persönliche Kontaktdaten aus Bekanntmachungen werden weder gespeichert noch angezeigt.